Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
QuintilesIMS
Citi
US Department of Justice
Accenture
Covington
UBS
Express Scripts
Chubb
Boehringer Ingelheim

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,758,891

« Back to Dashboard

Which drugs does patent 7,758,891 protect, and when does it expire?


Patent 7,758,891 protects ABRAXANE and is included in one NDA. There has been one Paragraph IV challenge on Abraxane.

This patent has seventy-six patent family members in twenty-five countries.

Summary for Patent: 7,758,891

Title:Combinations and modes of administration of therapeutic agents and combination therapy
Abstract: The present invention provides combination therapy methods of treating proliferative diseases (such as cancer) comprising a first therapy comprising administering to an individual an effective amount of a taxane in a nanoparticle composition, and a second therapy which may include, for example, radiation, surgery, administration of chemotherapeutic agents, or combinations thereof. Also provided are methods of administering to an individual a drug taxane in a nanoparticle composition based on a metronomic dosing regime.
Inventor(s): Desai; Neil P. (Los Angeles, CA), Soon-Shiong; Patrick (Los Angeles, CA)
Assignee: Abraxis Bioscience, LLC (Los Angeles, CA)
Application Number:12/334,115
Patent Claim Types:
see list of patent claims
Use; Composition;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Abraxis Bioscience
ABRAXANE
paclitaxel
FOR SUSPENSION;IV (INFUSION)021660-001Jan 7, 2005RXYesYes► Subscribe► Subscribe TREATMENT OF PANCREATIC CANCER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,758,891

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,735,394Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
7,780,984Methods and compositions for treating proliferative diseases► Subscribe
8,257,733Methods and compositions for treating proliferative diseases► Subscribe
8,268,348Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
9,101,543Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
8,034,375Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
9,561,288Combinations and modes of administration of therapeutic agents and combination therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,758,891

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel220547► Subscribe
Israel244390► Subscribe
Japan2008530248► Subscribe
Japan5769358► Subscribe
Japan2010509331► Subscribe
Japan5931323► Subscribe
Japan2014224157► Subscribe
Japan6092824► Subscribe
Japan2012193205► Subscribe
Japan2013064014► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Dow
Cantor Fitzgerald
Medtronic
Teva
UBS
Express Scripts
Queensland Health
Julphar
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot